Moreover, the metabolic effects of glucagon contribute to hepatic fat clearance in fatty liver disease models [32], suggesting glucagon-induced depletion of lipid stores may reduce viability in liver cancer cells that demand more fatty acids for growth. Here, GCG is linked to liver cancer.